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Abstract
The treatment of peritoneal surface malignancy mainly focuses on diffuse malignant peritoneal
mesothelioma, pseudomyxoma peritonei from appendiceal cancer, and peritoneal dissemination
from gastrointestinal and ovarian cancers. Cancer progression causes peritoneal implants to be
distributed throughout the abdominopelvic cavity. These nodules plus the ascitic fluid result in
abdominal distension. As the disease progresses, these tumors cause intestinal obstruction leading
to debilitating symptoms and a greatly impaired quality of life. In the past, the prognosis of patients
with peritoneal surface malignancy was regarded dismal and cure was not an option. Recently,
cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has shown an
improved survival in selected patients with this disease. To date, multiple different treatment
regimens of perioperative intraperitoneal chemotherapy have been used. This review focuses on
the perioperative intraperitoneal chemotherapy currently in use in conjunction with cytoreductive
surgery for the treatment of peritoneal surface malignancy at the Washington Cancer Institute.
Introduction
In the past peritoneal surface malignancy was considered
an incurable disease. Neither systemic chemotherapy nor
intraperitoneal chemotherapy alone had any significant
impact on survival. Palliative debulking surgery was
almost always associated with disease recurrence within a
few months. As the number of repeated debulking proce-
dures increased, patients were more likely to suffer from
intestinal obstruction and fistula formation. Eventually
failure of the treatments would lead to death. Recently
there have been an increasing number of publications
describing a comprehensive treatment approach that
involves cytoreductive surgery and perioperative intraperi-
toneal chemotherapy. [1-15].
Cytoreductive surgery consists of a series of peritonectomy
procedures and visceral resections aiming to maximally
eradicate visible tumor nodules on the parietal and vis-
ceral peritoneum. This is followed by perioperative intra-
peritoneal chemotherapy, immediately after the
cytoreductive surgery and during the early postoperative
period. Perioperative intraperitoneal chemotherapy tar-
gets specifically the microscopic residual disease in an
attempt to prolong disease-free survival and result in cure
for selected patients. This combined surgical and chemo-
therapeutic cytoreductive approach has demonstrated an
improved survival in selected patients with diffuse malig-
nant peritoneal mesothelioma (DMPM), pseudomyxoma
peritonei (PMP), and peritoneal dissemination from gas-
trointestinal and ovarian malignancies. [1-15].
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However, the treatment protocols of perioperative intra-
peritoneal chemotherapy vary from one institution to
another and there has been no real consensus on the most
effective regimens that should be used. This review
focuses on the pharmacologic information available for
the intraperitoneal chemotherapeutic agents routinely
used for peritoneal surface malignancy at the Washington
Cancer Institute, Washington DC.
Properties of Perioperative intraperitoneal chemotherapy
Drugs selected for intraperitoneal administration usually
are hydrophilic and have large molecular size, so that they
pass slowly through a peritoneal-plasma barrier and are
therefore more effectively sequestered in the peritoneal
cavity [16]. The area under the curve ratio of intraperito-
neal concentration to plasma concentration times time for
these drugs, indicates the amount of chemotherapy agent
that is sequestered in the peritoneal cavity to how much of
it is absorbed into the systemic circulation. A large perito-
neal to plasma ratio is an important property of intraperi-
toneal chemotherapy, because it maintains the maximal
concentration of the drug in the peritoneal cavity during
the chemotherapy washing, while not necessarily increas-
ing the systemic toxicities.
There are two time periods that have been utilized for
perioperative intraperitoneal chemotherapy administra-
tion, during the operation immediately after cytoreduc-
tive surgery and during the early postoperative period. The
drugs selected for intraoperative use must have some com-
mon properties [17,18]. First, they should be augmented
by heat, because heat has been found to potentiate the
cytotoxic effects of certain drug; also heat increases the
penetration of these drugs into tumor nodules and heat
itself exerts stress on tumor cells [19,20]. Second, the
drugs must have rapid cytotoxic effects on tumors during
the intraoperative drug administration period. The cyto-
toxicity should not be dependent upon cell division.
There are several different nomenclatures used for heated
intraoperative intraperitoneal chemotherapy (HIIC), such
as intraperitoneal hyperthermic chemoperfusion (IPHC)
and hyperthermic intraperitoneal chemotherapy
(HIPEC). In this review IPHC is used.
The drugs selected for administration in the early postop-
erative period require cell contact for a longer time peri-
ods to cause cytotoxic effects. Usually their activity is
dependent on cell division. At the Washington Cancer
Institute, the chemotherapy solution dwells for 23 hours
and then drains for one hour prior to the next instillation.
The instillation is repeated for the first 5 postoperative
days [21]. During this time period a minimal postopera-
tive adhesion process occurs, allowing a relatively uni-
form drug distribution of the intraperitoneal
chemotherapy.
Some institutions use IPHC only; some use early postop-
erative intraperitoneal chemotherapy (EPIC) only and
others use a combination of IPHC and EPIC.
Diffuse Malignant Peritoneal Mesothelioma (DMPM)
Natural history of DMPM
DMPM arises from the serosal lining of the abdominopel-
vic cavity, involving the parietal and visceral peritoneum.
It is characterized macroscopically by thousands of whit-
ish tumor nodules of variable size and consistency that
may coalesce to form plaques or masses or layer out to
uniformly cover the entire peritoneal surface [22]. DMPM
is commonly associated with debilitating ascites. In the
majority of patients the disease remains localized within
the abdominal and pelvic cavities throughout its course.
In contrast to mucinous carcinomatosis from appendiceal
cancer, the pattern of distribution of the peritoneal nod-
ules of DMPM does not spare mobile visceral surfaces of
the small bowel and its mesentery [22].
Intraperitoneal hyperthermic chemoperfusion for DMPM
After cytoreductive surgery, IPHC with doxorubicin (15
mg/m2) and cisplatin (50 mg/m2) is administered at
approximately 42°C in 1.5% dextrose peritoneal dialysis
solution for 90 minutes [11]. There is no pharmacological
incompatibility between these two drugs. Doxorubicin is
an antitumor antibiotic, which can be augmented by heat,
with an area under the curve ratio of 230 and a penetra-
tion of at least five cell layers [19]. It has a mild sclerosing
effect on the peritoneum when used at this standard dose.
This sclerotic effect is potentially effective in the manage-
ment of debilitating ascites in DMPM patients. [23-25].
Another favorable pharmacologic property of doxoru-
bicin is its ability to penetrate into tumor nodules. A
recent study demonstrated that the concentration of dox-
orubicin in the tumor nodules harvested during the intra-
operative chemotherapy instillation is even higher than
the concentration of doxorubicin in the intraperitoneal
fluid [26]. This suggests that there may be an active uptake
of doxorubicin by mesothelioma tumor nodules. A maxi-
mal chemotherapy response rate is therefore expected.
Cisplatin is an alkylating agent, with an area under the
curve ratio of 10 and the ability to penetrate tumor nod-
ules up to 3 mm at 41.5°C. The synergistic effect with heat
has been considered to be a result of higher and more
selective uptake of the drug by cancer cells [27]. It has
been used as an intraperitoneal drug for DMPM, gastric
cancer and ovarian cancer. Cisplatin is compatible with
multiple other agents, such as mitomycin C, doxorubicinJournal of Translational Medicine 2006, 4:17 http://www.translational-medicine.com/content/4/1/17
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and etoposide thus constituting a logical component of a
combination intraperitoneal chemotherapy regimen.
Early postoperative intraperitoneal chemotherapy for DMPM
EPIC with paclitaxel is used as the standard treatment for
patients with DMPM [11]. Paclitaxel is an antimitotic
drug that stabilizes microtubules and inhibits their depo-
lymerization for free tubulin. Its area under the curve ratio
is 1000 and can potentially penetrate up to 80 cell layers
[28]. These properties provide great advantage for the
intraperitoneal use of this drug. When paclitaxel is used in
hetastarch carrier solution, the artificial ascites created
exposes peritoneal surfaces to paclitaxel throughout each
23-hour dwell [29]. The hetastarch maintains an
increased volume of chemotherapy solution in the perito-
neal space as compared to a saline or dextrose solution,
with an increased surface exposure of the abdomen and
pelvis.
Our most recent update of 100 patients, who underwent
cytoreductive surgery and IPHC with cisplatin and doxo-
rubicin followed by EPIC with paclitaxel for DMPM,
showed that the median survival was 50 months and the
5-year survival was 44% [30].
Pseudomyxoma Peritonei (PMP)
Natural history of PMP
PMP is characterized by a copious mucin production by
adenomatous tumor cells. The neoplastic cells and
mucous ascites occupy predictable anatomic sites within
the peritoneal cavity. PMP is the paradigm for successful
treatment of peritoneal surface malignancy [4]. It is a min-
imally aggressive epithelial tumor, which has limited
capability of invading the peritoneum.
Appendiceal tumor initially obstructs the narrow lumen
of the appendix. This leads to appendiceal perforation,
which allows the tumor cells to access to the peritoneal
cavity. The adenomatous epithelial cells together with a
large volume of mucin accumulate at the sites of perito-
neal fluid absorption, such as the undersurface of the right
hemidiaphragm, the greater omentum, and within
dependent areas, such as pelvis, right retrohepatic space,
the left abdominal gutter and the ligament of Treitz [31].
The continuous peristaltic motion of the small intestine
prevents tumor implantation on its surfaces, which makes
cytoreductive procedure with preservation of adequate
small intestine feasible [4]. In contrast, the stomach and
the large bowel are invariably involved, but to a lesser
extent than quiescent surfaces such as liver and parietal
peritoneum.
Mucinous appendiceal tumors distribute intraperito-
neally; only rarely do they metastasize to lymph nodes or
liver. The seeding of the peritoneum by mucinous tumors
happens before lymph nodal or hepatic involvement [4].
After a complete cytoreduction, intraperitoneal chemo-
therapy can eradicate the microscopic residual disease.
Consequently tumor eradication from the peritoneal
space is usually possible and disease progression at sys-
tematic sites does not occur.
Intraperitoneal hyperthermic chemoperfusion for PMP
IPHC with mitomycin C is used for all patients with PMP.
It is also used in patients with peritoneal carcinomatosis
from other gastrointestinal cancers. Mitomycin C is an
antitumor antibiotic, with approximately 90% of the
drugs absorbed within the 90-minute intraperitoneal
instillation. The area under the curve ratio is approxi-
mately 30 and the drug can potentially penetrate up to 6
cell layers. The low plasma level when administered intra-
peritoneally reduces the risks of bone marrow toxicities
and hemolytic uremic syndrome [32]. However, even at
low plasma level, mitomycin C may cause renal damage.
Therefore it is important to provide forced diuresis intra-
operatively. A recent pharmacokinetic study on mitomy-
cin C dosimetry and toxicity demonstrated that volume of
chemotherapy solution was very important in determin-
ing drug absorption [33]. Currently all patients with PMP
receive 15 mg/m2 of mitomycin C in 1.5 L/m2 carrier solu-
tion at the Washington Cancer Institute.
Early postoperative intraperitoneal chemotherapy for PMP
5-fluorouracil is used for EPIC for peritoneal carcinoma-
tosis from appendiceal and other gastrointestinal malig-
nancies. This antimetabolite drug incorporates into the
DNA causing chain termination. The area under the curve
ratio is 250. Little 5-FU escapes into the systemic circula-
tion, as it is metabolized by single pass through the liver
via portal circulation. However, in patients with hepatic
dysfunction or when co-administered with mitomycin C,
a reduced dose of intraperitoneal 5-FU should be given.
A recent update on 803 patients with appendiceal epithe-
lial neoplasms with peritoneal dissemination who were
treated with cytoreductive surgery and IPHC with mito-
mycin C followed by EPIC with 5-FU over the last 20 years
showed that the overall 5-, 10-, and 20-year survival was
63%, 54% and 50%, respectively [34].
Colorectal Peritoneal Carcinomatosis (CRPC)
Natural history of CRPC
Colorectal cancer is the second most common cause of
cancer-related deaths in western countries. Peritoneal dis-
semination is present in 10% of patients at the time of
diagnosis [21]. The median survival of patients with
CRPC published by Chu et al and Sadeghi et al was 6
months and 5.2 months, respectively [35,36]. Newer
chemotherapeutic regimens have shown an improvedJournal of Translational Medicine 2006, 4:17 http://www.translational-medicine.com/content/4/1/17
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response rate, but the long-term prognosis remains uni-
formly poor. [37-41].
Perioperative intraperitoneal chemotherapy for CRPC
IPHC with mitomycin C, cisplatin and doxorubicin or
oxaliplatin combined with EPIC with 5-FU have been
used for gastrointestinal peritoneal carcinomatosis. Oxali-
platin has been used intraperitoneally in Europe for color-
ectal peritoneal carcinomatosis, as pioneered by Elias and
colleagues [42,43]. IPHC with oxaliplatin has a very low
area under the curve ratio, which means that this drug is
rapidly absorbed and does not require a long dwell time
in the peritoneal cavity for maximal local-regional effect
[42]. Elias and co-workers suggested that intraperitoneal
oxaliplatin should be combined with intravenous 5-FU as
just before IPHC [43]. This bi-directional use of intrave-
nous and intraperitoneal chemotherapy theoretically
exerts greater cytotoxic effects via both capillary network
and passive diffusion. Elias et al showed that intravenous
5-FU at 400 mg/m2 combined with IPHC with 460 mg/m2
of oxaliplatin in 2 L/m2 of peritoneal solution over 30
minutes, achieved a median survival of 60 months and a
5-year survival of 49% [43]. All patients had an optimal
cytoreduction prior to the IPHC.
We participated in a recent international registry study of
506 patients with colorectal carcinomatosis treated by
cytoreduction and perioperative intraperitoneal chemo-
therapy with a curative intent from 28 institutions. This
study demonstrated that the overall median survival was
19.2 months [15]. Our recent update showed 3- and 5-
year survival of 44% and 32% in 70 patients who under-
went complete cytoreduction and PIC for CRPC [44].
Gastric Peritoneal Carcinomatosis (GPC)
Natural history of GPC
The annual incidence of gastric cancer in the United States
is 22,400 and approximately 14,400 patients die of the
disease. At the time of surgery 20–30% of patients with
gastric cancer being explored for potentially curative resec-
tion will be found to have peritoneal seeding [24,25,45].
Forty to fifty percent of patients who had undergone cur-
ative resection developed locoregional recurrence one to
three years after their initial surgery [45]. Even at death,
the tumor often remains confined to the abdomen [45].
The tumor cell entrapment hypothesis suggests that surgi-
cal manipulation of the cancer-bearing organs, transec-
tion of lymphatic channels and blood loss from the cancer
specimen results in free intraperitoneal cancer cells. These
cancer cells are embedded in fibrin, as the wound-healing
process is initiated [45].
Current standard treatment is systemic chemotherapy for
patients with GPC, which may delay onset of symptoms,
but does not have any significant impact on survival. The
high incidence of isolated peritoneal carcinomatosis from
gastric cancer suggests that cytoreductive surgery and peri-
operative intraperitoneal chemotherapy in selected
patients could result in improved survival.
Perioperative intraperitoneal chemotherapy for GPC
Cytoreductive surgery is combined with hyperthermic
intraperitoneal perfusion with mitomycin C, cisplatin and
etoposide [46]. A recent study reported to use neoadju-
vant intraperitoneal chemotherapy with docetaxel and
carboplatin combined with intravenous methotrexate and
5-FU for advanced GPC [47].
Ovarian Peritoneal Carcinomatosis (OPC)
Natural history of OPC
Epithelial ovarian cancer accounts for 80–90% of all ovar-
ian malignancies and is the main cause of death for all
gynecological tumors [48]. Tumor dissemination is fre-
quently confined to the peritoneal cavity. Papillary serous
carcinoma of the peritoneum is an extra-ovarian primary
peritoneal carcinoma. The epithelial layer of the ovary
and the peritoneum have a common origin from the coe-
lomic epithelium. Cytoreductive surgery is considered as
the standard of care for ovarian malignancies. This is usu-
ally followed with systemic chemotherapy as most
patients with ovarian cancer are chemotherapy sensitive
and a prolonged survival is expected [49,50]. However,
disease recurrence is common and often resistant to addi-
tional treatment with systemic chemotherapy. There is a
potential role for cytoreductive surgery combined with
perioperative intraperitoneal chemotherapy for advanced
primary and recurrent epithelial ovarian cancers and pap-
illary serous carcinoma of the peritoneum. In our previ-
ous update of 28 female patients who underwent
cytoreductive surgery and IPHC or EPIC for OPC, the
median survival was 46 months [14].
Perioperative intraperitoneal chemotherapy for OPC
Prevention and eradication of peritoneal carcinomatosis
through the use of intraperitoneal chemotherapy was
declared standard of practice by the National Cancer Insti-
tute, Bethesda, USA after a recent phase III study in ovar-
ian cancer [51]. Cyclophosphamide is the only
chemotherapeutic agent approved by the U.S. Food and
Drug Administration for intraperitoneal use and is very
effective against ovarian cancer. However, from a pharma-
cologic standpoint, it needs to be activated by hepatic
microsomal enzymes, which makes it theoretically inef-
fective for intraperitoneal use. Both ifosfamide and cyclo-
phosphamide are markedly synergized by heat. These
drugs may double their cytotoxicity for cancer cells when
used with hyperthermia [52]. When used intravenously
these drugs are "heat targeted" to the warm peritoneal sur-
face resulting from IPHC. A study is underway to investi-Journal of Translational Medicine 2006, 4:17 http://www.translational-medicine.com/content/4/1/17
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gate IPHC of cisplatin and doxorubicin combined with
intravenous ifosfamide after cytoreductive surgery for
peritoneal dissemination from advanced primary or
recurrent epithelial ovarian cancer and papillary serous
carcinoma. It is hoped that this bi-directional local-
regional and systemic chemotherapy treatment will result
in an improved survival in these patients.
Future directions
Standardization of treatment protocols
This comprehensive treatment of cytoreductive surgery
combined with perioperative intraperitoneal chemother-
apy has shown long-term survival in selected patients with
DMPM, PMP, and peritoneal dissemination from other
gastrointestinal and ovarian cancers. However, there has
been little uniformity in the surgical approach or the
chemotherapeutic regimens used. A standardization of
the treatment protocols is necessary, for multi-institu-
tional treatment plans to provide meaningful data. Some
new concepts regarding neoadjuvant chemotherapy, bi-
directional chemotherapy, and adjuvant chemotherapy
for treatment and prevention of disease recurrence are the-
oretically appealing.
Neoadjuvant chemotherapy
Yonemura and co-workers used neoadjuvant intraperito-
neal and systemic (NIPS) chemotherapy in patients with
GPC to downstage the tumor volume [47]. After NIPS
they achieved complete tumor resection in 25% of
patients [47]. Theoretically, this chemoselection approach
can also be used in patients with CRPC. The prognosis in
both diseases is heavily dependent on the tumor volume
at the time of surgical exploration.
Bi-directional chemotherapy
The extent of intraperitoneal chemotherapy penetrating
tumor nodules by passive diffusion is limited to a few cell
layers. Elias and colleagues have been using hyperthermic
intravenous chemotherapy in combination with intra-
peritoneal chemotherapy to achieve a greater response.
The cytotoxic effects result not only from penetration
within the tumor via the capillary network but also by pas-
sive diffusion from the peritoneal space. In a recent study
they have reported a 5-year survival rate of 49% in 30
patients who underwent complete cytoreduction for
CRPC [43]. However, it remains unclear in terms of how
much of the improved survival is contributed by the bi-
directional perioperative chemotherapy treatment and
how much of it is due to the patient selection. All their
patients treated with perioperative chemotherapy had a
complete cytoreduction. It would be interesting to see if
this bi-directional chemotherapy approach can pharma-
cologically improve chemotherapy penetration and more
importantly if this approach can broaden the scope of
patients who can potentially benefit from cytoreductive
surgery and perioperative intraperitoneal chemotherapy.
Adjuvant intraperitoneal chemotherapy
The peritoneal surface is a frequent site of tumor recur-
rence after primary cancer surgery. This occurs because
free cancer cells are shed from the primary tumor or
present in blood and lymph in the surgical field. In some
patients it is impossible to avoid dissemination of cancer
cells during surgical manipulation. Yu and co-workers
reported an improved survival in patients who received
adjuvant intraperitoneal chemotherapy for advanced gas-
tric cancer [53]. Xu and colleagues have recently suggested
in a meta-analysis an improved management of advanced
gastric cancer when IPHC was used in conjunction with
complete resection (Hazard ratio: 0.51 and 95% confi-
dence interval: 0.40 – 0.65) [54]. In 8 of the 11 studies,
mitomycin C was used.
When all the data is considered together it may not be
unreasonable to use perioperative chemotherapy in all
gastrointestinal patients who are at higher risk of develop-
ing local recurrence or peritoneal dissemination. These are
the patients who have full thickness cancer involvement
of the lumenal wall, bowel perforation, localized perito-
neal implants, Krukenberg's tumors and in patients where
an en-bloc removal of tumor is not achieved.
In summary, this review focused on the perioperative
intraperitoneal chemotherapy currently used for the treat-
ment of peritoneal surface malignancy at the Washington
Cancer Institute. There is a need to standardize the treat-
ment regimens and consider incorporating perioperative
intraperitoneal chemotherapy not only in the manage-
ment of biopsy proven carcinomatosis, but also in the
treatment of primary disease.
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